ClinicalTrials.gg
CompletedNCT05818085Updated Dec 22, 2025

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

A Phase 2/3 interventional study of ABP-671 and Allopurinol in Gout, sponsored by Atom Therapeutics Co., Ltd. Completed at 57 sites in 5 countries. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Atom Therapeutics Co., Ltd · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
26th of 149
300 · median 74
Started
2023
with 5 others
Phase 2/3
3 of 164
1 open now
Registered
141st of 164
by date
Lead sponsor
5 of 164
Atom Therapeutics Co., Ltd

Among the 164 studies in Gout with a site in United States, this one is the 26th largest by enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 2/3, and was the 141st registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged ≥19 and \<70 years of age at the time of .
  • A (BMI) of ≥18 kg/m2 to ≤40 kg/m2.
  • Diagnosis of gout per American College of Rheumatology/European Alliance of Associations for Rheumatology 2015 Gout Classification Criteria and must meet the criteria as follows:

    • At Screening, participants with gout on ULT (including allopurinol) must be willing to discontinue ULT.
    • At Screening, participants with gout who are not currently treated with any UA lowering therapy must have an sUA ≥7.5 mg/dL (≥0.450 mmol/L).
  • At the confirmatory sUA visit, all participants must have an sUA ≥7.0 mg/dL (≥0.420 mmol/L).
  • Women of (WOCBP) must be surgically sterile (eg, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or willing to use acceptable and highly effective double from Screening until at least 30 days after the last dose of the study drug. Double contraception is defined as a condom AND one other form of the following:

    • Established hormonal contraception (with approved oral contraceptive pills, long-acting implantable hormones, injectable hormones);
    • A vaginal ring or an intrauterine device OR
    • Documented evidence of surgical sterilization at least 6 months prior to Screening (eg, tubal occlusion, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy for women or vasectomy for men [with appropriate post-vasectomy documentation of the absence of sperm in semen] provided the male partner is the sole partner). The absence of records will not exclude screening the participant; if medical records cannot be obtained, serum pregnancy testing will be conducted to confirm the participant is not pregnant.

Note: Women not of childbearing potential must be for ≥12 months. Postmenopausal status will be confirmed through follicle stimulating hormone (FSH) concentration testing.

-Men must be surgically sterile (>30 days since vasectomy), abstinent, or if engaged in sexual relations with a female partner of childbearing potential, the participant must use an acceptable form of contraception from Screening until at least 30 days after the last dose of the study drug. Acceptable methods of contraception include the use of condoms in addition to the use of an effective contraceptive for the female partner that includes approved oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device. Participants who practice abstinence (abstinence from penile-vaginal intercourse) are eligible when this is in line with their preferred and usual lifestyle. In addition, men must not donate sperm for at least 30 days after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

  • History of rheumatoid arthritis or other disease.
  • hepatic, cardiovascular, renal, neoplastic, psychiatric, or hematological disorders such as polycythemia vera, sickle cell disease, or myelodysplastic disorder.
  • Positive test result for , surface antigen, or virus antibody. Active hepatitis C virus infection is defined as a participant with a positive hepatitis C antibody and detectable hepatitis C viral load RNA.
  • Participants who, in the opinion of the Investigator, have a high genetic risk of allopurinol syndrome unless they have been found to be negative for Human leukocyte antigen (HLA)-B*5801, either clinically by prior exposure to allopurinol or by laboratory evaluation.
  • Liver function tests >2x the laboratory (ULN) range of , alkaline phosphatase, or alanine aminotransferase; total >1.5x ULN at Screening.
  • Inadequate renal function with serum creatinine >1.5 mg/dL (>0.133 mmol/L) or estimated (eGFR) \< 60 mL/min/m2 (by the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine-based eGFR equation).
  • History of within the previous 5 years; with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia, or treated in situ grade 1 cervical cancer.
  • History within the last 12 months of unstable angina, functional class III or IV heart failure, myocardial infarction, stroke, venous thromboembolism, or a history of percutaneous coronary intervention.
  • Uncontrolled hypertension (systolic BP ≥160 mmHg and/or diastolic BP ≥90 mmHg). If BP is controlled while taking antihypertensive medication, the participant must be on stable dose for previous 2 months.
  • Active liver disease or impaired hepatic function as assessed by liver function tests.
  • Received any therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening.
  • Any other medical or psychological condition, that, in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the participant, interfere with the participant's ability to comply with the protocol requirements to complete the study, or potentially compromise the results or interpretation of the study.
  • Pregnant, breastfeeding, or planning a pregnancy during the study or ≤30 days after the last dose of the study drug.
  • Intolerant or unwilling to take colchicine or naproxen.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    ABP-671

    Drug: ABP-671

  • Active comparator
    Allopurinol

    Drug: Allopurinol

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Low, medium or high dose (Part 1); Selected dose(s) (Part 2)

  • Standard of care according to American College of Rheumatology (ACR) guideline for the management of gout

  • OtherPlacebo

    ABP-671 matching placebo

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)

    Time frame: Week 28

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (Safety and Tolerability)

    Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation

    Time frame: Week 28

  2. Proportion of participants who achieve sUA levels <5.0 mg/dL (<0.300 mmol/L)

    Time frame: Week 28

07

Study locations

57 sites
  • Alliance for Multispecialty Research
    Tempe, Arizona 85281, United States
  • Tucson Neuroscience Research, LLC
    Tuscon, Arizona 85710, United States
  • Anaheim Clinical Trials (Cenexel ACT)
    Anaheim, California 92801, United States
  • Center for Clinical Trials of Sacramento
    Sacramento, California 95823, United States
  • Access Research Institute
    Brooksville, Florida 34613, United States
  • Nature Coast Clinical Reasearch
    Crystal River, Florida 34429, United States
  • JY Research Institute Inc.
    Cutler Bay, Florida 33189, United States
  • Accel Clinical Research Site
    DeLand, Florida 32720, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Accel Research Sites Network - St. Pete-Largo Clinical Research Unit
    Largo, Florida 33777, United States
  • A & D Doctor Center
    Miami, Florida 33135, United States
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
  • Cordova Research Institute
    Miami, Florida 33155, United States
  • Century Research LLC
    Miami, Florida 33173, United States
  • ITB Research
    Miami, Florida 33173, United States
  • Combined Research Orlando Phase I-IV
    Orlando, Florida 32807, United States
  • New Horizons Research
    Palmetto Bay, Florida 33158, United States
  • Advanced Clinical Research of Atlanta
    Atlanta, Georgia 30309, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Alliance for Multispecialty Research, LLC.
    Newton, Kansas 67114, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • AMR
    New Orleans, Louisiana 70119, United States
  • Annapolis Internal Medicine/CCT Research
    Annapolis, Maryland 21401, United States
  • DelRicht Research of Gulfport
    Gulfport, Mississippi 39501, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Santa Rosa Medical Center
    Las Vegas, Nevada 89119, United States
  • Inspire Santa Fe Medical Group
    Santa Fe, New Mexico 87505, United States
  • OnSite Clinical Solutions
    Salisbury, North Carolina 28144, United States
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Medical Care/CCT
    Elizabethton, Tennessee 37643, United States
  • PanAmerican Clinical Research, LLC
    Brownsville, Texas 78520, United States
  • Quality Research Inc.
    San Antonio, Texas 78209, United States
  • Centricity Research
    Suffolk, Virginia 23435, United States
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Emeritus Research Sydney
    Botany, New South Wales 2019, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, New South Wales 2259, Australia
  • A R Houston Medical Pty Ltd
    Kippa-Ring, Queensland 4021, Australia
  • Emeritus Research Melbourne
    Camberwell, Victoria 3124, Australia
  • Austin Health - Repatriation Hospital
    Heidelberg, Victoria 3084, Australia
  • New Hospitals
    Tbilisi, 0114, Georgia
  • Evex Hospitals Caraps Medline
    Tbilisi, 0159, Georgia
  • Aversi Clini
    Tbilisi, 0160, Georgia
  • The First Medical Center
    Tbilisi, 0180, Georgia
  • Academician Vakhtang Bochorishvili Clinic
    Tbilisi, 0186, Georgia
  • Innova
    Tbilisi, 0186, Georgia
  • Clinical Research Center (CRC)
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna y Reumatología (CREER)
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna y Reumatología
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna
    Guatemala City, 01010, Guatemala
  • Clínica Médica Especializada en Medicina Interna y Reumatología
    Guatemala City, 1011, Guatemala
  • Buddhist Dalin Tzu Chi General Hospital
    Chiayi City, 62247, Taiwan
  • Chang Gung Memorial Hospital CGMH
    Kaohsiung City, 833, Taiwan
  • Chung Shan Medical Univ. Hospital
    Taichung, 402367, Taiwan
  • Cheng-Shin General Hospital
    Taipei, 112401, Taiwan
  • Chang Gung Memorial Hospital LinKou
    Taoyuan, 333423, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jan 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
Aug 11, 2023
Primary completionActual
Jan 30, 2025
CompletionActual
Mar 30, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05818085
Lead sponsor
Atom Therapeutics Co., Ltd
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Aug 11, 2023
Primary completion
Jan 30, 2025
Completion
Mar 30, 2025
Last update
Dec 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-671

Start the discussion